Dr. Ken-ryu Han

Dr. Ken-ryu Han
Dr. Han is fellowship-trained in urologic cancers with a focus on prostate, bladder, kidney, and testicular cancers. In addition to urologic cancer, his areas of specialty include kidney stone disease and prostate conditions. Dr. Han’s work has been extensively published including over 40 scientific papers and over 10 national research presentations. His paper on Cryosurgery for the treatment of organ-confined prostate cancer with third-generation cryosurgery, preliminary multi-center experience, was the first paper in the world on the use of the technology in humans. Before joining Arizona Urology Specialists in 2009, Dr. Han was in practice at Canyon State Urology. Dr. Han grew up in Southern California. His interests include spending time with his wife and four children, running, and rooting for the Las Vegas Raiders. Memberships American Urological Association American Urological Association, Western Section Fellow of the American College of Surgeons Education College Undergraduate Cornell University Ithaca, NY Medical School George Washington University Medical School Washington, DC Residency Urology Robert Wood Johnson University Hospital New Brunswick, NJ Internship Surgical Robert Wood Johnson University Hospital New Brunswick, NJ Fellowship Fellowship focusing on prostate, bladder, kidney, and testicular cancers UCLA Los Angeles, CA Board Certification American Board of Urology
Medical School:

George Washington University

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only